Emrullah HAYTA, Ahmet KARADAĞ, Mehmet TÜRKMEN, Hasan ELDEN

The clinical significance of the anti-RA33 level in patients with rheumatoid arthritis

Amaç: RA tanısının erken konulması, tedavi ile eklem dokusundaki hasarın önüne geçilebilmesi açısından çok önemlidir. Laboratuar testleri, RA aktivitesinin izlenmesinde ve tedaviye yanıtın değerlendirilmesinde oldukça önemlidir. RA şüphesi olan vakalarda bugüne kadar en yaygın kullanılan test romatoid faktördür, RA'ya duyarlı olmasına rağmen özgül olmayan bir parametredir. Şüpheli vakalarda ya da düşük RF sevyeli vakalarda otoantikor ölçümü tanı koymada yardımcı olabilir. Anti RA-33 otoantikor ölçümü RA'lı hastalarda kullanılan otoantikor testlerinden biridir. Bu çalışmanın amacı sağlıklı bireyler ile RA'lı bireylerin Anti-RA 33 seviyesini karşılaştırmak ve Anti-RA 33 seviyesinin RA tanısında önemini değerlendirmektir. Yöntem: American College of Rheumatology (ACR) RA klasifikasyon kriterlerine göre belirlenmiş hastalık süresi en az iki yıl olan 28 i bayan,12 si erkek toplam 40 RA'li hasta ile aynı sayıda kontrol grubu sağlıklı kişiler çalışmaya alındı. Bulgular: RA'li hasta grubunda AntiRA-33 düzeyi 12,47±49,76 U/ml, sağlıklı kontrol grubunda AntiRA-33 düzeyi 1,96±1.82 U/ml olup gruplar arası istatiksel olarak bir fark bulunmadı. Sonuç: RA'lı hastalarda AntiRA-33 düzeyi ile sağlıklı kontrol grubu arasında anlamlı bir fark bulunamadı.

Romatoid artritli hastalarda Anti-Ra 33 seviyesinin klinik önemi

Objective: The early diagnosis of Rheumatoid Arthritis (RA) is of due significance for the prevention of possible damage to the joint tissue by means of treatment. Laboratory tests are very important for monitoring RA activity and for the evaluation of the patients' response to the treatment. Rheumatoid factor, so far the most commonly used test for the cases with suspected RA, is not a specific parameter despite its sensitivity to RA. The measurement of other autoantibodies might be helpful to the diagnosis particularly for the cases with low RF titer or with suspected diagnosis. The measurement of anti-RA33 autoantibodies is one of the tests used in the diagnosis of the RA cases. The present study was conducted to compare anti-RA33 levels of healthy individuals with long-term RA cases and to evaluate the value of anti-RA33 test for the RA diagnosis. Method: Total 40 patients (28 female and 12 male) identified with RA at least for the last five years according to the classification criteria of American College of Rheumatology (ACR) reviewed in 1987 and 40 healthy controls included in the present study. Results: AntiRA-33 level was determined as 12.47±4.97 U/mL for the patients with RA and as 1.96±1.82 U/mL for the healthy controls, and there is no statistically significant difference between the groups. Conclusions: As a result AntiRA-33 level was evaluated in RA patients and no difference was found compared to control group.

PDF

___

Maini RN, Zvaifler NJ: Rheumatoid arthritis and spondyloarthropathy. Klippel JH, Dieppe PA (ed). Rheumatology. St Louis: Mosby, 1994; 3: 1-4.
Bottini N, Firestein GS. Epigenetics in rheumatoid arthritis: a primer for rheumatologists. Curr Rheumatol Rep. 2013; 15: 372.
Gramling A, O'Dell JR. Initial management of rheumatoid arthritis. Rheum Dis Clin North Am. 2012; 38: 311-25.
Renaudineau Y, Jamin C, Saraux A, Youinou P. Rheumatoid factor on a daily basis. Autoimmunity 2005; 38: 11-6.
Schoels M, Bombardier C, Aletaha D. Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated peripheral inflammatory arthritis: a systematic review. J Rheumatol Suppl 2011; 87: 20-5.
Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van venrooij WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin İnvest 1998; 101: 273-81.
Firestein GS: Etiology and pathogenesis of rheumatoid arthritis. Harris ED, Budd CR Firestein GS (ed), Kelley's Textbook of Rheumatology. Seventh (7th) edition Philadelphia, 2005: 996-1042.
Aho K, Steiner G, Kurki P, Paimela L, Leirisalo-Repo M, Palosuo T,et al.Anti-RA 33 as a marker antibody of rheumatoid arthritis in a Finnish population. Clin Exp Rheumatol.1993; 11: 645-7.
Meyer O, Tauxe F, Fabregas D,Gabay C, Goycochea M, Haim T, et al. Anti-RA 33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol. 1993; 11: 473-8.
Van Boekel M, Vossenaar, ER, van den Hoogen, FHJ, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Research 2001; 4: 87-93.
Levin RW, Park J, Ostrov B,Reginato A, Baker DG, Bomalaski JS, et al. A cross-sectional and longitudinal comparison of the Rome criteria for active rheumatoid arthritis (equivalent to the American College of Rheumatology 1958 criteria) and the American College of Rheumatology 1987 criteria for rheumatoid arthritis. Arthritis Rheum. 1994; 37: 1479-86.
Schellekens GA, Visser H, de Jong BAW, van den Hoogen FH, Hazes JM, Breedeveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing anti-cyclic citrulinated peptide. Arthritis Rheum, 2000; 43:155-63.
S. Rantapää-Dahlqvist, B.A.W. de Jong, E. Berglin Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003; 48:2741-9.
Westwood OM, Nelson PN, Hay FC. Rheumatoid factors: what's new? Rheumatology 2006; 45: 379- 85.
Khurana R, Berney SM. Clinical aspects of rheumatoid arthritis. Pathophysiology 2005; 12: 153-65.
Gabay C, Prieur AM, Meyer O. Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. Ann Rheum Dis 1993; 52): 785-9.
Hueber W, Hassfeld W, Smolen JS, Steiner G. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford). 1999; 38: 155-9.
Cordonnier C, Meyer O, Palazzo E, de Bandt M, Elias A, Nicaise P, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996; 35: 620-4.
Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005; 64: 1731-6.
Zhou ZJ, Jiang M, Song QF. Evaluation of anti-rheumatoid arthritis 36 kD and anti-33 kD antibodies in the diagnosis of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi. 1994; 33: 251-4.
Tomoum HY, Mostafa GA, El Shahat EM. Autoantibody to heterogeneous nuclear ribonucleoprotein-A2 (RA33) in juvenile idiopathic arthritis: clinical significanc. Pediatr Int 2009; 51: 188-92.
Luban S, Li ZG.Citrullinated peptide and its relevance to rheumatoid arthritis: an update.Int J Rheum Dis 2010; 13: 284-7.
Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 731-4.
Zintzaras E, Papathanasiou AA, Ziogas DC, Voulgarelis M.The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates. BMC Musculoskelet Disord 2012; 13: 113.
Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012; 51: 5-9.